Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study

被引：12

作者：

Piccaluga, Pier Paolo ^{[1
]}

Malagola, Michele ^{[2
]}

Rondoni, Michela ^{[1
]}

Arpinati, Mario ^{[1
]}

Paolini, Stefania ^{[1
]}

Candoni, Anna ^{[1
]}

Fanin, Renato ^{[3
]}

Messa, Emanuela ^{[4
]}

Pirrotta, Maria Teresa ^{[5
]}

Lauria, Francesco ^{[5
]}

Visani, Giuseppe ^{[6
]}

Alberti, Daniele

Rancati, Francesca

Vinaccia, Vincenza ^{[7
]}

Russo, Domenico

Saglio, Giuseppe ^{[4
]}

Baccarani, Michele ^{[1
]}

Martinelli, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Hosp, Inst Hematol & Med Oncol L & A Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy

[2] Univ Brescia, Dept Hematol, Brescia, Italy

[3] Univ Udine, Dept Hematol, Udine, Italy

[4] Univ Torino, Dept Hematol, Orbassano, Turin, Italy

[5] Univ Siena, Dept Hematol, Siena, Italy

[6] Dept Hematol, Pesaro, Italy

[7] Novartis Pharmaceut, Origgio, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 12期

关键词：

imatinib mesylate; acute myeloid leukemia; c-KIT; PDGFRB; targeted therapy;

D O I：

10.3324/haematol.11345

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

引用

页码：1721 / 1722

页数：2

共 50 条

[1] A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML)
Advani, Anjali
Cooper, Brenda
Sowunmi, Olumuyiwa
Elson, Paul
Ali-Osman, Francis
Park, Jino
Rao, Arati
Rizzieri, David A.
Wang, Eunice S.
Cotta, Claudiu
Sekeres, Mikkael A.
Kalaycio, Matt
Sobecks, Ronald
Rouphail, Basel
Maciejewski, Jaroslaw P.
Davis, Randall
Bailey, Laura
Foster, Bethany
Rush, Mary Lynn
Adams, Donna
Tse, William
BLOOD, 2012, 120 (21)
[2] A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit-positive Acute Myeloid Leukemia
Advani, Anjali S.
Tse, William
Li, Hong
Jia, Xuefei
Elson, Paul
Cooper, Brenda
Ali-Osman, Francis
Park, Jino
Rao, Arati, V
Rizzieri, David A.
Wang, Eunice S.
Cotta, Claudiu, V
Kalaycio, Matt
Sobecks, Ronald M.
Rouphail, Basel
Maciejewski, Jaroslaw P.
Fensterl, Jaime
Carew, Jennifer S.
Foster, Bethany
Rush, Mary Lynn
Tripp, Barbara
Adams, Donna
Corrigan, Donna
Griffiths, Elizabeth A.
Sekeres, Mikkael A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (02): : 113 - 118
[3] A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
Advani, Anjali S.
Tiu, Ramon
Saunthararajah, Yogen
Maciejewski, Jaroslaw
Copelan, Edward A.
Sobecks, Ronald
Sekeres, Mikkael A.
Bates, Jennifer
Rush, Mary Lynn
Tripp, Barbara
Salvado, August
Noon, Elysa
Howard, Matthew
Jin, Tao
Hsi, Eric
Egorin, Merrill J.
Lim, Kathleen
Cotta, Claudiu V.
Price, Courtney
Kalaycio, Matt
LEUKEMIA RESEARCH, 2010, 34 (12) : 1622 - 1626
[4] The efficacy and safety of imatinib in adult patients with C-Kit positive acute myeloid leukemia.
Kindler, T
Breitenbuecher, F
Marx, A
Beck, J
Hess, G
Weinkauf, B
Duyster, J
Peschel, C
Kirkpatrick, CJ
Theobald, M
Gschaidmeier, H
Huber, C
Fischer, T
BLOOD, 2003, 102 (11) : 871A - 871A
[5] A phase II pilot study of Gleevec/Glivec (imatinib mesylate, STI-571) in patients with c-kit positive acute myeloid leukemia (AML).
Fischer, T
Beck, J
Duyster, J
Peschel, C
Müller-Navia, J
Jäger, E
Knuth, A
Gschaidmeier, H
Huber, C
BLOOD, 2002, 100 (11) : 561A - 561A
[6] Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)
Advani, Anjali S.
Tse, William
Jia, Xuefei
Elson, Paul
Cooper, Brenda
Ali-Osman, Francis
Park, Jino
Rao, Arati V.
Rizzieri, David A.
Wang, Eunice S.
Cotta, Claudiu V.
Kalaycio, Matt
Sobecks, Ronald M.
Rouphail, Basel
Maciejewski, Jaroslaw P.
Fensterl, Jaime
Bailey, Laura
Carew, Jennifer S.
Foster, Bethany
Rush, Mary Lynn
Adams, Donna
Griffiths, Elizabeth A.
Sekeres, Mikkael A.
BLOOD, 2015, 126 (23)
[7] Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia:: is this the real target?
Malagola, M
Martinelli, G
Rondoni, M
Paolini, S
Gaitani, S
Arpinati, M
Piccaluga, PP
Amabile, M
Basi, C
Ottaviani, E
Candoni, A
Gottardi, E
Cilloni, D
Bocchia, M
Saglio, G
Lauria, F
Fanin, R
Visani, G
Marré, MC
Maderna, M
Rancati, F
Vinaccia, V
Russo, D
Baccarani, M
BLOOD, 2005, 105 (02) : 904 - 904
[8] Remission in a patient with c-kit positive refractory acute myelogenous leukemia after imatinib treatment
Yildirim, Z
Grant, BW
Liu, XLS
Branda, RR
Cushman, M
Holmes, CE
Tindle, BH
BLOOD, 2002, 100 (11) : 266B - 266B
[9] A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)
Advani, Anjali S.
Sobecks, Ronald
Sekeres, Mikkael A.
Copelan, Ed
Bates, Jennifer
Tripp, Barbara
Salvado, August
Kalaycio, Matt
BLOOD, 2007, 110 (11) : 276A - 276A
[10] Experience with imatinib in a paediatric patient with C-kit positive refractory acute myeloid leukaemia
Andres, M. M.
Moreno, L.
Bautista, F. J.
Fernandez Navarro, J. M.
Fernandez Sanmartin, M.
Verdeguer, A.
BONE MARROW TRANSPLANTATION, 2008, 41 : S435 - S436

← 1 2 3 4 5 →